₹617.95
Overview of Glenmark Life Sciences Ltd
Nirma Ltd has agreed to acquire a 75% stake in Glenmark Life Sciences for ₹5,651.5 crore and will make a mandatory open offer for an additional 17.15% stake at ₹631/share. Meanwhile, Glenmark Pharma is set to sell its majority stake in the life sciences unit for $680 million.
Nirma Acquires Majority Stake in Glenmark Life Sciences - 21 Sep, 2023
Glenmark Pharmaceuticals sells a 75% stake in Glenmark Life Sciences to Nirma Ltd for Rs 5,652 crore. The company will operate independently under new ownership.
Glenmark Life Sciences Included in Nifty 500 Index - 17 Aug, 2023
Glenmark Life Sciences Ltd will be added to the Nifty 500 index, as per a recent announcement.
Glenmark Life Sciences Added to MSCI Global Small Cap Index - 11 Aug, 2023
Glenmark Life Sciences Ltd has been added to the MSCI Global Smallcap Index, effective from August 31.
Nirma Eyes Acquisition of Glenmark Life Sciences - 28 Jul, 2023
Nirma is planning to acquire companies in the healthcare sector and has shortlisted Glenmark Life Sciences for financial bids. The acquisition will help Nirma diversify its portfolio.
Nirma Group Shortlisted for Glenmark Life Sciences Bid - 27 Jul, 2023
Glenmark Life Sciences witnesses remarkable growth, touching a 52-week high of Rs 673.2. Nirma Group is shortlisted to make a financial bid for the company, which may cost up to Rs 6,000 crore.
Glenmark Life Sciences Reports Strong Q1 Results and Successful IPO - 21 Jul, 2023
Glenmark Life Sciences reports a 24% YoY increase in net profit for Q1 2023, while its IPO is subscribed 2.78 times on the second day of bidding, leading to a new 52-week high at Rs. 658.
Nirma and Sekhmet among final bidders for controlling stake in Glenmark Life Sciences - 15 Jul, 2023
Nirma Ltd. and Sekhmet Pharmaventures, backed by PAG, are among the final bidders for a controlling stake in Glenmark Life Sciences valued at about $731 million. The move comes as Glenmark Pharma looks to raise cash and cut debt.
Shortlisted Bidders for Controlling Stake in Glenmark Life Sciences - 14 Jul, 2023
Nirma Ltd. and PAG-backed Sekhmet Pharmaventures are among the shortlisted bidders for a controlling stake in Glenmark Life Sciences Ltd.
Source: S&P Global Market Intelligence
0.15%
Downside
Day's Volatility:1.59%
Upside
1.45%
40.12%
Downside
52 Weeks Volatility:49.36%
Upside
9.23%
Returns % | |
1 Month Return | 0.61 % |
3 Month Return | 9.26 % |
1 Year Return | 63.47 % |
Market Stats | |
Previous Close | ₹621.85 |
Open | ₹623.90 |
Volume | 1.82L |
Market Cap | ₹7,619.35Cr |
Organisation | Glenmark Life Sciences Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Fundamentals of Glenmark Life Sciences Ltd
Mutual Funds have increased holdings from 0.00% to 0.52% in Jun 2023 quarter
In the last 6 months, GLS stock has moved up by 62.6%
In the last 1 year, GLS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Promoters holdings remained unchanged at 82.85% of holdings in Jun 2023 quarter
Foreign Institutions have decreased holdings from 3.29% to 3.27% in Jun 2023 quarter
Retail Investor have decreased holdings from 13.86% to 13.30% in Jun 2023 quarter
Funds | Holdings |
![]() | 0.98% |
![]() | 1.39% |
![]() | 1.44% |
![]() | 0.98% |
![]() | 0.7% |
Investors | Holdings % | Prev. 2 periods | 3M change |
---|---|---|---|
Promoter Holdings | 82.85% | 0.00 | |
Foreign Institutions | 3.27% | ||
Mutual Funds | 0.52% | 257800.00 | |
Retail Investors | 13.3% | ||
Others | 0.06% | 8371.43 |
Technicals of Glenmark Life Sciences Ltd share
News & Events of Glenmark Life Sciences Ltd
Glenmark Life Sciences Ltd(GLS | Price |
---|---|
52 Week High | ₹675 |
52 Week Low | ₹370 |
Glenmark Life Sciences Ltd(GLS | Returns |
---|---|
1 Day Returns | -3.9% |
1 Month Returns | 0.61% |
3 Month Returns | 9.26% |
1 Year Returns | 63.47% |